Monitor the outcome of the Nasdaq hearing request. If the appeal fails, delisting would likely lead to a significant loss of liquidity and a potential further decline in the stock price.
CRIS drugs
CRIS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.6976entry
- T+1 · 7d ago −6.39%α −6.03% · $0.6530
- T+5 · 20h ago −37.53%α −35.84% · $0.4358
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Curis received a delisting determination letter from Nasdaq on November 2, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days. The company is not eligible for a compliance period because it effected a 1-for-20 reverse stock split on July 6, 2026, and is subject to a Discretionary Panel Monitor. Curis intends to request a hearing to stay delisting, but there is no assurance of success.
Key Facts
- Nasdaq notified Curis on November 2, 2026, that its bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- Curis effected a 1-for-20 reverse stock split on July 6, 2026, making it ineligible for a compliance period under Rule 5810(c)(3)(A)(iv).
- Curis is subject to a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for one year following a Panel decision dated July 24, 2026.
- The company intends to request a hearing with the Panel to stay delisting, but success is not assured.
Financial Impact
Market cap is $7M; delisting would severely reduce liquidity and institutional ownership.
Risk Factors
- Delisting would reduce liquidity and institutional ownership, potentially leading to further price declines.
- The company has already used a reverse stock split within the past year, limiting its options to regain compliance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-123906 |
| Document: 0001104659-26-123906-index-headers.html | 0001104659-26-123906 |
| Document: 0001104659-26-123906-index.html | 0001104659-26-123906 |
| Document: 0001104659-26-123906.txt | 0001104659-26-123906 |
Track record
18 reports on CRIS
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
- Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
- Nov 6, 202610d ago 8-K Bearish 7/10 Viewing Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
- Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
- Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers